{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,7,9]],"date-time":"2024-07-09T19:40:45Z","timestamp":1720554045564},"reference-count":112,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2006,4,1]],"date-time":"2006-04-01T00:00:00Z","timestamp":1143849600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Seminars in Oncology"],"published-print":{"date-parts":[[2006,4]]},"DOI":"10.1053\/j.seminoncol.2006.01.021","type":"journal-article","created":{"date-parts":[[2006,4,19]],"date-time":"2006-04-19T17:45:15Z","timestamp":1145468715000},"page":"26-39","source":"Crossref","is-referenced-by-count":6,"special_numbering":"S4","title":["Treatment of Cancer-Associated Thrombosis: Distinguishing Among Antithrombotic Agents"],"prefix":"10.1053","volume":"33","author":[{"given":"Jane","family":"Pruemer","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1053\/j.seminoncol.2006.01.021_bib1","series-title":"Pharmacotherapy","first-page":"295","article-title":"Thromboembolic disorders","author":"Erdman","year":"2000"},{"key":"10.1053\/j.seminoncol.2006.01.021_bib2","doi-asserted-by":"crossref","first-page":"2212","DOI":"10.1161\/01.CIR.93.12.2212","article-title":"Management of deep vein thrombosis and pulmonary embolism. A statement for healthcare professionals","volume":"93","author":"Hirsh","year":"1996","journal-title":"Circulation"},{"key":"10.1053\/j.seminoncol.2006.01.021_bib3","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1007\/BF01209121","article-title":"Studies on tumor cell-induced platelet aggregation in human lung cancer cell lines","volume":"122","author":"Heinmoller","year":"1996","journal-title":"J Cancer Res Clin Oncol"},{"key":"10.1053\/j.seminoncol.2006.01.021_bib4","first-page":"58","article-title":"Platelet-aggregating activities of metastasizing tumor cells","volume":"6","author":"Tohgo","year":"1986","journal-title":"Invasion Metastasis"},{"key":"10.1053\/j.seminoncol.2006.01.021_bib5","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1172\/JCI117451","article-title":"Tissue factor controls the balance of angiogenic and antiangiogenic properties of tumor cells in mice","volume":"94","author":"Zhang","year":"1994","journal-title":"J Clin Invest"},{"issue":"suppl 3","key":"10.1053\/j.seminoncol.2006.01.021_bib6","first-page":"66","article-title":"Treatment of venous thromboembolism in cancer patients","volume":"28","author":"Levine","year":"1998","journal-title":"Haemostasis"},{"key":"10.1053\/j.seminoncol.2006.01.021_bib7","series-title":"Pathology for Surgeons","author":"Spence","year":"1993"},{"issue":"suppl 1","key":"10.1053\/j.seminoncol.2006.01.021_bib8","first-page":"I9","article-title":"Risk factors for venous thromboembolism","volume":"107","author":"Anderson","year":"2003","journal-title":"Circulation"},{"issue":"suppl 1","key":"10.1053\/j.seminoncol.2006.01.021_bib9","doi-asserted-by":"crossref","first-page":"132S","DOI":"10.1378\/chest.119.1_suppl.132S","article-title":"Prevention of venous thromboembolism","volume":"119","author":"Geerts","year":"2001","journal-title":"Chest"},{"key":"10.1053\/j.seminoncol.2006.01.021_bib10","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1016\/S0140-6736(98)10266-0","article-title":"Venous thrombosis","volume":"353","author":"Rosendaal","year":"1999","journal-title":"Lancet"},{"issue":"suppl 1","key":"10.1053\/j.seminoncol.2006.01.021_bib11","first-page":"I17","article-title":"Venous thromboembolism and cancer","volume":"107","author":"Lee","year":"2003","journal-title":"Circulation"},{"key":"10.1053\/j.seminoncol.2006.01.021_bib12","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1097\/00005792-199909000-00001","article-title":"Rates of initial and recurrent thromboembolic disease among patients with malignancy versus those without malignancy. Risk analysis using Medicare claims data","volume":"78","author":"Levitan","year":"1999","journal-title":"Medicine (Baltimore)"},{"key":"10.1053\/j.seminoncol.2006.01.021_bib13","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1001\/archinte.160.6.809","article-title":"Risk factors for deep vein thrombosis and pulmonary embolism","volume":"160","author":"Heit","year":"2000","journal-title":"Arch Intern Med"},{"key":"10.1053\/j.seminoncol.2006.01.021_bib14","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1002\/1097-0142(19841001)54:7<1264::AID-CNCR2820540706>3.0.CO;2-R","article-title":"Increased incidence of thromboembolism in stage IV breast cancer patients treated with a five-drug chemotherapy regimen","volume":"54","author":"Goodnough","year":"1984","journal-title":"Cancer"},{"key":"10.1053\/j.seminoncol.2006.01.021_bib15","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1016\/j.amjmed.2004.03.040","article-title":"Adverse effects of thalidomide administration in patients with neoplastic diseases","volume":"117","author":"Dimopoulos","year":"2004","journal-title":"Am J Med"},{"key":"10.1053\/j.seminoncol.2006.01.021_bib16","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1016\/j.ygyno.2004.10.023","article-title":"Thromboembolic events in patients treated with definitive chemotherapy and radiation therapy for invasive cervical cancer","volume":"96","author":"Jacobson","year":"2005","journal-title":"Gynecol Oncol"},{"key":"10.1053\/j.seminoncol.2006.01.021_bib17","first-page":"567","article-title":"Thrombotic complications during L-asparaginase treatment for acute lymphocytic leukemia","volume":"75","author":"Castaman","year":"1990","journal-title":"Hematologica"},{"key":"10.1053\/j.seminoncol.2006.01.021_bib18","doi-asserted-by":"crossref","first-page":"2659","DOI":"10.1016\/j.ejca.2004.06.013","article-title":"Portal vein thrombosis during antineoplastic chemotherapy in children","volume":"40","author":"Brisse","year":"2004","journal-title":"Eur J Cancer"},{"key":"10.1053\/j.seminoncol.2006.01.021_bib19","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1001\/jama.293.6.715","article-title":"Malignancies, prothrombotic mutations, and the risk of venous thrombosis","volume":"293","author":"Blom","year":"2005","journal-title":"JAMA"},{"key":"10.1053\/j.seminoncol.2006.01.021_bib20","doi-asserted-by":"crossref","first-page":"3484","DOI":"10.1182\/blood-2002-01-0108","article-title":"Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis","volume":"100","author":"Prandoni","year":"2002","journal-title":"Blood"},{"issue":"suppl 3","key":"10.1053\/j.seminoncol.2006.01.021_bib21","doi-asserted-by":"crossref","first-page":"401S","DOI":"10.1378\/chest.126.3_suppl.401S","article-title":"Antithrombotic therapy for venous thromboembolic disease","volume":"126","author":"Buller","year":"2004","journal-title":"Chest"},{"key":"10.1053\/j.seminoncol.2006.01.021_bib22","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1055\/s-2002-36701","article-title":"Thromboembolic disease in surgery for malignancy\u2014Rationale for prolonged thromboprophylaxis","volume":"28","author":"Khushal","year":"2002","journal-title":"Semin Thromb Hemost"},{"key":"10.1053\/j.seminoncol.2006.01.021_bib23","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/0049-3848(79)90159-2","article-title":"Molecular weight dependency of the heparin potentiated inhibition of thrombin and activated factor X","volume":"5","author":"Andersson","year":"1979","journal-title":"Thromb Res"},{"issue":"suppl","key":"10.1053\/j.seminoncol.2006.01.021_bib24","first-page":"12","article-title":"Pharmacology of low molecular weight heparins","volume":"16","author":"Harenberg","year":"1990","journal-title":"Semin Thromb Hemost"},{"key":"10.1053\/j.seminoncol.2006.01.021_bib25","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/S0008-6215(00)84041-0","article-title":"The molecular weight range of commercial heparin preparations","volume":"51","author":"Johnson","year":"1976","journal-title":"Carbohydr Res"},{"key":"10.1053\/j.seminoncol.2006.01.021_bib26","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1016\/0006-291X(76)90558-1","article-title":"The separation of active and inactive forms of heparin","volume":"69","author":"Lam","year":"1976","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1053\/j.seminoncol.2006.01.021_bib27","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/0049-3848(76)90105-5","article-title":"Anticoagulant properties of heparin fractionated by affinity chromatography on matrix-bound antithrombin III and by gel filtration","volume":"9","author":"Andersson","year":"1976","journal-title":"Thromb Res"},{"key":"10.1053\/j.seminoncol.2006.01.021_bib28","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1111\/j.1600-0609.1971.tb01976.x","article-title":"Inhibition of thrombin-induced aggregation of human platelets in heparin","volume":"8","author":"Eika","year":"1971","journal-title":"Scand J Hematol"},{"key":"10.1053\/j.seminoncol.2006.01.021_bib29","first-page":"259","article-title":"Bleeding associated with antithrombotic therapy","volume":"17","author":"Kelton","year":"1980","journal-title":"Semin Hematol"},{"key":"10.1053\/j.seminoncol.2006.01.021_bib30","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/0049-3848(86)90094-0","article-title":"Hemorrhagic doses of heparin and other glycosaminoglycans induce a platelet defect","volume":"43","author":"Fernandez","year":"1986","journal-title":"Thromb Res"},{"key":"10.1053\/j.seminoncol.2006.01.021_bib31","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1111\/j.1749-6632.1989.tb22507.x","article-title":"Effects of unfractionated heparin, dermatan sulfate and low molecular weight heparin on vessel wall permeability in rabbits","volume":"556","author":"Blajchman","year":"1989","journal-title":"Ann NY Acad Sci"},{"key":"10.1053\/j.seminoncol.2006.01.021_bib32","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/0049-3848(82)90006-8","article-title":"Comparison of the in vivo hemorrhagic and antithrombotic effects of a low antithrombin III affinity heparin fraction","volume":"27","author":"Ockelford","year":"1982","journal-title":"Thromb Res"},{"key":"10.1053\/j.seminoncol.2006.01.021_bib33","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1038\/265625a0","article-title":"Suppression by heparin of smooth muscle cell proliferation in injured arteries","volume":"265","author":"Clowes","year":"1977","journal-title":"Nature"},{"key":"10.1053\/j.seminoncol.2006.01.021_bib34","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1182\/blood.V86.4.1368.bloodjournal8641368","article-title":"The effects of low molecular weight and standard heparin on calcium loss from the fetal rat calvaria","volume":"86","author":"Shaughnessy","year":"1995","journal-title":"Blood"},{"key":"10.1053\/j.seminoncol.2006.01.021_bib35","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1055\/s-0037-1615222","article-title":"The effects of standard and low molecular weight heparin on bone nodule formation in vitro","volume":"80","author":"Bhandari","year":"1998","journal-title":"Thromb Haemost"},{"key":"10.1053\/j.seminoncol.2006.01.021_bib36","doi-asserted-by":"crossref","first-page":"11256","DOI":"10.1016\/S0021-9258(18)33750-5","article-title":"Inhibition of vascular smooth muscle cell growth by endothelial cell-derived heparin","volume":"257","author":"Castellot","year":"1982","journal-title":"J Biol Chem"},{"key":"10.1053\/j.seminoncol.2006.01.021_bib37","series-title":"Hemostasis and Thrombosis","first-page":"837","article-title":"The heparin-antithrombin system","author":"Rosenberg","year":"1994"},{"key":"10.1053\/j.seminoncol.2006.01.021_bib38","doi-asserted-by":"crossref","first-page":"15467","DOI":"10.1016\/S0021-9258(18)66735-3","article-title":"Role of ternary complexes, in which heparin binds both antithrombin and proteinase, in the acceleration of the reactions between antithrombin and thrombin or factor Xa","volume":"261","author":"Danielsson","year":"1986","journal-title":"J Biol Chem"},{"key":"10.1053\/j.seminoncol.2006.01.021_bib39","doi-asserted-by":"crossref","first-page":"10081","DOI":"10.1016\/S0021-9258(19)70431-1","article-title":"The kinetics of hemostatic enzyme-antithrombin interactions in the presence of low molecular weight heparin","volume":"255","author":"Jordan","year":"1980","journal-title":"J Biol Chem"},{"issue":"suppl","key":"10.1053\/j.seminoncol.2006.01.021_bib40","doi-asserted-by":"crossref","first-page":"64S","DOI":"10.1378\/chest.119.1_suppl.64S","article-title":"Heparin and low-molecular-weight heparin","volume":"119","author":"Hirsh","year":"2001","journal-title":"Chest"},{"key":"10.1053\/j.seminoncol.2006.01.021_bib41","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1056\/NEJM199709043371007","article-title":"Low-molecular-weight heparins","volume":"337","author":"Weitz","year":"1997","journal-title":"N Engl J Med"},{"issue":"suppl 2","key":"10.1053\/j.seminoncol.2006.01.021_bib42","first-page":"48","article-title":"Physiological function of tissue factor pathway inhibitor and interaction with heparins","volume":"30","author":"Sandset","year":"2000","journal-title":"Haemostasis"},{"issue":"suppl","key":"10.1053\/j.seminoncol.2006.01.021_bib43","first-page":"16S","article-title":"Basic and applied pharmacology of low molecular weight heparins","author":"Fareed","year":"1995","journal-title":"Pharmacol Ther"},{"key":"10.1053\/j.seminoncol.2006.01.021_bib44","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1111\/j.1538-7836.2005.01125.x","article-title":"A potential pharmacogenomic strategy for anticoagulant treatment in non-ST elevation acute coronary syndromes","volume":"3","author":"Ray","year":"2005","journal-title":"J Thromb Haemost"},{"key":"10.1053\/j.seminoncol.2006.01.021_bib45","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1016\/S0002-9149(03)00105-X","article-title":"Comparison of effects on markers of blood cell activation of enoxaparin, dalteparin, and unfractionated heparin in patients with unstable angina pectoris or non-ST-segment elevation acute myocardial infarction (the ARMADA study)","volume":"91","author":"Montalescot","year":"2003","journal-title":"Am J Cardiol"},{"issue":"suppl 1","key":"10.1053\/j.seminoncol.2006.01.021_bib46","first-page":"89","article-title":"Differentiation of low-molecular-weight heparins","volume":"30","author":"Fareed","year":"2004","journal-title":"Semin Thromb Hemost"},{"key":"10.1053\/j.seminoncol.2006.01.021_bib47","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1055\/s-0037-1615131","article-title":"Heparin and cancer","volume":"80","author":"Zacharski","year":"1998","journal-title":"Thromb Haemost"},{"key":"10.1053\/j.seminoncol.2006.01.021_bib48","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1007\/BF00280041","article-title":"Dose adjusted heparin treatment of deep venous thrombosis","volume":"39","author":"Handeland","year":"1990","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1053\/j.seminoncol.2006.01.021_bib49","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1056\/NEJM199603143341101","article-title":"A comparison of low-molecular-weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep-vein thrombosis","volume":"334","author":"Levine","year":"1996","journal-title":"N Engl J Med"},{"key":"10.1053\/j.seminoncol.2006.01.021_bib50","doi-asserted-by":"crossref","first-page":"2298","DOI":"10.1001\/archinte.159.19.2298","article-title":"Economic evaluation of outpatient treatment with low-molecular-weight heparin for proximal vein thrombosis","volume":"159","author":"O\u2019Brien","year":"1999","journal-title":"Arch Intern Med"},{"key":"10.1053\/j.seminoncol.2006.01.021_bib51","doi-asserted-by":"crossref","first-page":"298","DOI":"10.18553\/jmcp.2000.6.4.298","article-title":"Outcomes analyses of the outpatient treatment of venous thromboembolic disease using the low-molecular-weight heparin enoxaparin in a managed care organization","volume":"6","author":"Spyropoulos","year":"2000","journal-title":"J Managed Care Pharm"},{"key":"10.1053\/j.seminoncol.2006.01.021_bib52","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1056\/NEJM199505183322003","article-title":"Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin","volume":"332","author":"Warkentin","year":"1995","journal-title":"N Engl J Med"},{"key":"10.1053\/j.seminoncol.2006.01.021_bib53","series-title":"US Pharmacist HS3-HS23","article-title":"Low-molecular-weight heparins for deep vein thrombosis","author":"LaPointe","year":"2001"},{"key":"10.1053\/j.seminoncol.2006.01.021_bib54","series-title":"Heparin-Induced Thrombocytopenia","first-page":"291","article-title":"Treatment of heparin-induced thrombocytopenia. An Overview","author":"Greinacher","year":"2001"},{"issue":"suppl 1","key":"10.1053\/j.seminoncol.2006.01.021_bib55","first-page":"14","article-title":"Can we differentiate the low-molecular-weight heparins?","volume":"23","author":"Turpie","year":"2000","journal-title":"Clin Cardiol"},{"issue":"suppl 1","key":"10.1053\/j.seminoncol.2006.01.021_bib56","doi-asserted-by":"crossref","first-page":"176S","DOI":"10.1378\/chest.119.1_suppl.176S","article-title":"Antithrombotic therapy for venous thromboembolic disease","volume":"119","author":"Hyers","year":"2001","journal-title":"Chest"},{"key":"10.1053\/j.seminoncol.2006.01.021_bib57","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1378\/chest.126.3_suppl.311S","article-title":"Heparin-induced thrombocytopenia: recognition, treatment, and prevention: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy","volume":"126","author":"Warkentin","year":"2004","journal-title":"Chest"},{"key":"10.1053\/j.seminoncol.2006.01.021_bib58","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.hoc.2004.09.003","article-title":"Unfractionated heparin, low molecular weight heparins, and pentasaccharide","volume":"19","author":"Bick","year":"2005","journal-title":"Hematol Oncol Clin North Am"},{"key":"10.1053\/j.seminoncol.2006.01.021_bib59","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1056\/NEJMoa025313","article-title":"Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer","volume":"349","author":"Lee","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1053\/j.seminoncol.2006.01.021_bib60","first-page":"235","article-title":"Management of thrombosis in the cancer patient","volume":"1","author":"Andrea","year":"2003","journal-title":"J Supportive Oncol"},{"key":"10.1053\/j.seminoncol.2006.01.021_bib61","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1001\/archinte.156.8.851","article-title":"Ardeparin (low-molecular-weight heparin) vs graduated compression stockings for the prevention of venous thromboembolism. A randomized trial in patients undergoing knee surgery","volume":"156","author":"Levine","year":"1996","journal-title":"Arch Intern Med"},{"key":"10.1053\/j.seminoncol.2006.01.021_bib62","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1056\/NEJM199603143341102","article-title":"Treatment of venous thromboembolism with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low molecular weight heparin administered at home","volume":"334","author":"Koopman","year":"1996","journal-title":"N Engl J Med"},{"key":"10.1053\/j.seminoncol.2006.01.021_bib63","series-title":"Coumadin (warfarin sodium) Prescribing Information","year":"2002"},{"key":"10.1053\/j.seminoncol.2006.01.021_bib64","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1177\/1358836X9800300114","article-title":"Long-term, low-dose warfarin among venous thrombosis patients with and without factor V Leiden mutation","volume":"3","author":"Ridker","year":"1998","journal-title":"Vasc Med"},{"key":"10.1053\/j.seminoncol.2006.01.021_bib65","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1056\/NEJMoa035029","article-title":"Long-term, low-intensity warfarin therapy for the prevention of recurrent venous thromboembolism","volume":"348","author":"Ridker","year":"2003","journal-title":"N Engl J Med"},{"issue":"suppl 1","key":"10.1053\/j.seminoncol.2006.01.021_bib66","doi-asserted-by":"crossref","first-page":"I10","DOI":"10.1161\/01.CIR.0000140902.46296.ae","article-title":"Long-term management of patients after venous thromboembolism","volume":"110","author":"Kearon","year":"2004","journal-title":"Circulation"},{"issue":"suppl 3","key":"10.1053\/j.seminoncol.2006.01.021_bib67","doi-asserted-by":"crossref","first-page":"338S","DOI":"10.1378\/chest.126.3_suppl.338S","article-title":"Prevention of venous thromboembolism","volume":"126","author":"Geerts","year":"2004","journal-title":"Chest"},{"key":"10.1053\/j.seminoncol.2006.01.021_bib68","first-page":"15","article-title":"Fondaparinux for the prevention of VTE in acutely ill medical patients","volume":"102","author":"Cohen","year":"2003","journal-title":"Blood"},{"key":"10.1053\/j.seminoncol.2006.01.021_bib69","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1056\/NEJM199204093261502","article-title":"Subcutaneous low-molecular-weight heparin compared with continuous intravenous heparin in the treatment of proximal-vein thrombosis","volume":"326","author":"Hull","year":"1992","journal-title":"N Engl J Med"},{"key":"10.1053\/j.seminoncol.2006.01.021_bib70","doi-asserted-by":"crossref","first-page":"1","DOI":"10.7326\/0003-4819-123-1-199507010-00001","article-title":"Comparing subcutaneous danaparoid with intravenous unfractionated heparin for the treatment of venous thromboembolism. A randomized controlled trial","volume":"123","author":"de Valk","year":"1995","journal-title":"Ann Int Med"},{"key":"10.1053\/j.seminoncol.2006.01.021_bib71","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1136\/bmj.309.6950.299","article-title":"Comparison of efficacy and safety of low molecular weight heparins and unfractionated heparin in initial treatment of deep venous thrombosis","volume":"309","author":"Leizorovicz","year":"1994","journal-title":"BMJ"},{"key":"10.1053\/j.seminoncol.2006.01.021_bib72","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1001\/archinte.155.6.601","article-title":"Treatment of deep venous thrombosis with low-molecular-weight heparins. A meta-analysis","volume":"155","author":"Lensing","year":"1995","journal-title":"Arch Intern Med"},{"key":"10.1053\/j.seminoncol.2006.01.021_bib73","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1016\/S0002-9610(99)80222-0","article-title":"A comparative trial of a low molecular weight heparin (enoxaparin) versus standard heparin for the prophylaxis of postoperative deep vein thrombosis in general surgery","volume":"169","author":"Nurmohamed","year":"1995","journal-title":"Am J Surg"},{"key":"10.1053\/j.seminoncol.2006.01.021_bib74","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1001\/archinte.160.2.181","article-title":"A meta-analysis comparing low molecular-weight heparins with unfractionated heparin in the treatment of venous thromboembolism","volume":"160","author":"Dolovich","year":"2000","journal-title":"Arch Intern Med"},{"issue":"suppl 1","key":"10.1053\/j.seminoncol.2006.01.021_bib75","article-title":"A randomized double-blind study to compare the efficacy and safety of fondaparinux with dalteparin in the prevention of venous thromboembolism after high-risk abdominal surgery","volume":"1","author":"Agnelli","year":"2003","journal-title":"J Thrombos Haemost"},{"key":"10.1053\/j.seminoncol.2006.01.021_bib76","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1002\/bjs.1800840817","article-title":"Efficacy and safety of enoxaparin versus unfractionated heparin for prevention of deep vein thrombosis in elective cancer surgery","volume":"84","year":"1997","journal-title":"Br J Surg"},{"key":"10.1053\/j.seminoncol.2006.01.021_bib77","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1056\/NEJMoa012385","article-title":"Duration of prophylaxis against venous thromboembolism with enoxaparin after surgery for cancer","volume":"346","author":"Bergqvist","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1053\/j.seminoncol.2006.01.021_bib78","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1016\/S0140-6736(94)90008-6","article-title":"Double-blind randomised trial of a very-low-dose warfarin for prevention of thromboembolism in stage IV breast cancer","volume":"343","author":"Levine","year":"1994","journal-title":"Lancet"},{"key":"10.1053\/j.seminoncol.2006.01.021_bib79","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/S0002-9343(97)89484-3","article-title":"Low-molecular-weight heparins and unfractionated heparin in the treatment of patients with acute venous thromboembolism","volume":"100","author":"Siragusa","year":"1996","journal-title":"Am J Med"},{"key":"10.1053\/j.seminoncol.2006.01.021_bib80","doi-asserted-by":"crossref","first-page":"800","DOI":"10.7326\/0003-4819-130-10-199905180-00003","article-title":"Low-molecular-weight heparins compared with unfractionated heparin for treatment of acute deep venous thrombosis. A meta-analysis of randomized, controlled trials","volume":"130","author":"Gould","year":"1999","journal-title":"Ann Intern Med"},{"key":"10.1053\/j.seminoncol.2006.01.021_bib81","first-page":"437","article-title":"Cancer and venous thromboembolism","volume":"84","author":"Prandoni","year":"1999","journal-title":"Haematologica"},{"issue":"suppl 1","key":"10.1053\/j.seminoncol.2006.01.021_bib82","article-title":"Low molecular-weight heparin for the long-term treatment of symptomatic venous thromboembolism","volume":"1","author":"Iorio","year":"2003","journal-title":"J Thromb Haemost"},{"key":"10.1053\/j.seminoncol.2006.01.021_bib83","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1001\/archinte.162.15.1729","article-title":"Comparison of low-molecular-weight heparin and warfarin for secondary prevention of venous thromboembolism in patients with cancer","volume":"162","author":"Meyer","year":"2002","journal-title":"Arch Intern Med"},{"key":"10.1053\/j.seminoncol.2006.01.021_bib84","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1111\/j.1538-7836.2004.00853.x","article-title":"Fixed-dose low-molecular-weight heparin for secondary prevention of venous thromboembolism in patients with disseminated cancer","volume":"2","author":"Monreal","year":"2004","journal-title":"J Thromb Haemost"},{"key":"10.1053\/j.seminoncol.2006.01.021_bib85","doi-asserted-by":"crossref","first-page":"1476","DOI":"10.1016\/0140-6736(92)92064-M","article-title":"Lower mortality in cancer patients treated with low-molecular-weight versus standard heparin","volume":"339","author":"Green","year":"1992","journal-title":"Lancet"},{"key":"10.1053\/j.seminoncol.2006.01.021_bib86","doi-asserted-by":"crossref","first-page":"1944","DOI":"10.1200\/JCO.2004.10.002","article-title":"Low molecular weight heparin, therapy with dalteparin, and survival in advanced cancer","volume":"22","author":"Kakkar","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2006.01.021_bib87","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1111\/j.1538-7836.2004.00871.x","article-title":"A randomized clinical trial of combination chemotherapy with and without low-molecular-weight heparin in small cell lung cancer","volume":"2","author":"Altinbas","year":"2004","journal-title":"J Thromb Haemost"},{"key":"10.1053\/j.seminoncol.2006.01.021_bib88","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1159\/000081508","article-title":"Low-molecular-weight heparin and cancer survival","volume":"33","author":"Conti","year":"2003","journal-title":"Pathophysiol Haemost Thromb"},{"key":"10.1053\/j.seminoncol.2006.01.021_bib89","doi-asserted-by":"crossref","first-page":"2130","DOI":"10.1200\/JCO.2005.03.134","article-title":"The effect of low molecular weight heparin on survival in patients with advanced malignancy","volume":"10","author":"Klerk","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2006.01.021_bib90","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1200\/JCO.2005.03.133","article-title":"Randomized comparison of low molecular weight heparin and coumarin derivatives on the survival of patients with cancer and venous thromboembolism","volume":"23","author":"Lee","year":"2005","journal-title":"J Clin Oncol"},{"issue":"suppl 1","key":"10.1053\/j.seminoncol.2006.01.021_bib91","article-title":"(LITE Investigators)","volume":"1","author":"Hull","year":"2003","journal-title":"J Thromb Haemost"},{"key":"10.1053\/j.seminoncol.2006.01.021_bib92","first-page":"498","article-title":"Current and potential uses of low molecular weight heparin","volume":"6","author":"Seo","year":"2000","journal-title":"Am J Managed Care"},{"issue":"suppl 20","key":"10.1053\/j.seminoncol.2006.01.021_bib93","first-page":"S1034","article-title":"Outpatient-based treatment protocols in the management of venous thromboembolic disease","volume":"6","author":"Spyropoulos","year":"2000","journal-title":"Am J Managed Care"},{"issue":"suppl 20","key":"10.1053\/j.seminoncol.2006.01.021_bib94","first-page":"S1054","article-title":"Economics of low-molecular weight heparins","volume":"6","author":"Rutschmann","year":"2000","journal-title":"Am J Managed Care"},{"key":"10.1053\/j.seminoncol.2006.01.021_bib95","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2165\/00019053-200017010-00001","article-title":"Formulary management of low molecular weight heparins","volume":"17","author":"Wade","year":"2000","journal-title":"Pharmacoeconomics"},{"issue":"suppl 3","key":"10.1053\/j.seminoncol.2006.01.021_bib96","first-page":"8","article-title":"The economic impact of treating deep vein thrombosis with low-molecular-weight heparin","volume":"28","author":"Hull","year":"1998","journal-title":"Haemostasis"},{"issue":"suppl 6","key":"10.1053\/j.seminoncol.2006.01.021_bib97","doi-asserted-by":"crossref","first-page":"S15","DOI":"10.1093\/ajhp\/59.suppl_6.S15","article-title":"Breaking out of the silo","volume":"59","author":"Vichiendilokkul","year":"2002","journal-title":"Am J Health Syst Pharm"},{"key":"10.1053\/j.seminoncol.2006.01.021_bib98","doi-asserted-by":"crossref","first-page":"789","DOI":"10.7326\/0003-4819-130-10-199905180-00002","article-title":"Low-molecular-weight heparins compared with unfractionated heparin for treatment of acute deep venous thrombosis. A cost-effectiveness analysis","volume":"130","author":"Gould","year":"1999","journal-title":"Ann Intern Med"},{"issue":"suppl D","key":"10.1053\/j.seminoncol.2006.01.021_bib99","first-page":"18","article-title":"The pharmacoeconomics of low molecular-weight heparins","volume":"16","author":"Groce","year":"2001","journal-title":"Consult Pharm"},{"key":"10.1053\/j.seminoncol.2006.01.021_bib100","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1016\/S0002-9149(99)00341-0","article-title":"Use of enoxaparin for the chronically anticoagulated patient before and after procedures","volume":"84","author":"Spandorfer","year":"1999","journal-title":"Am J Cardiol"},{"issue":"suppl 2","key":"10.1053\/j.seminoncol.2006.01.021_bib101","first-page":"360S","article-title":"Cost effectiveness and safety of outpatient bridge therapy","volume":"116","author":"Smith","year":"1999","journal-title":"Chest"},{"key":"10.1053\/j.seminoncol.2006.01.021_bib102","doi-asserted-by":"crossref","first-page":"1642","DOI":"10.1378\/chest.125.5.1642","article-title":"Costs and clinical outcomes associated with low-molecular-weight heparin vs unfractionated heparin for perioperative bridging in patients receiving long-term oral anticoagulant therapy","volume":"125","author":"Spyropoulos","year":"2004","journal-title":"Chest"},{"key":"10.1053\/j.seminoncol.2006.01.021_bib103","first-page":"1950","article-title":"American Society of Health-System Pharmacists Commission on Therapeutics","volume":"61","year":"2004","journal-title":"Am J Health Syst Pharm"},{"key":"10.1053\/j.seminoncol.2006.01.021_bib104","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.1001\/jama.270.14.1672","article-title":"From the Food and Drug Administration","volume":"270","author":"Nightingale","year":"1993","journal-title":"JAMA"},{"key":"10.1053\/j.seminoncol.2006.01.021_bib105","doi-asserted-by":"crossref","first-page":"163S","DOI":"10.1378\/chest.126.3_suppl.172S","article-title":"The Seventh ACCP Consensus Conference on Antithrombotic Therapy","volume":"126","author":"Hirsh","year":"2004","journal-title":"Chest"},{"key":"10.1053\/j.seminoncol.2006.01.021_bib106","doi-asserted-by":"crossref","first-page":"983","DOI":"10.2174\/1381612043452811","article-title":"Biochemical and pharmacologic heterogeneity in low molecular weight heparins","volume":"10","author":"Fareed","year":"2004","journal-title":"Curr Pharm Des"},{"key":"10.1053\/j.seminoncol.2006.01.021_bib107","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.hoc.2004.09.005","article-title":"Development of generic low molecular weight heparins","volume":"19","author":"Fareed","year":"2005","journal-title":"Hematol Oncol Clin North Am"},{"key":"10.1053\/j.seminoncol.2006.01.021_bib108","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1345\/aph.10264","article-title":"Therapeutic equivalency of low-molecular-weight heparins","volume":"36","author":"McCart","year":"2002","journal-title":"Ann Pharmacother"},{"key":"10.1053\/j.seminoncol.2006.01.021_bib109","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1001\/archinte.165.7.733","article-title":"A randomized trial comparing 2 low-molecular-weight heparins for the outpatient treatment of deep vein thrombosis and pulmonary embolism","volume":"165","author":"Wells","year":"2005","journal-title":"Arch Intern Med"},{"key":"10.1053\/j.seminoncol.2006.01.021_bib110","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1093\/annonc\/mdi165","article-title":"Deep vein thrombosis in cancer","volume":"16","author":"Falanga","year":"2005","journal-title":"Ann Oncol"},{"key":"10.1053\/j.seminoncol.2006.01.021_bib111","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1093\/ajhp\/59.6.534","article-title":"Survey of hospital policies regarding low-molecular-weight heparins","volume":"59","author":"Schumock","year":"2002","journal-title":"Am J Health Syst Pharm"},{"issue":"suppl D","key":"10.1053\/j.seminoncol.2006.01.021_bib112","first-page":"7","article-title":"DVT\/pulmonary embolism prophylaxis in medically ill patients","volume":"16","author":"Groce","year":"2001","journal-title":"Consult Pharm"}],"container-title":["Seminars in Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0093775406000509?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0093775406000509?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2021,7,25]],"date-time":"2021-07-25T21:07:16Z","timestamp":1627247236000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0093775406000509"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,4]]},"references-count":112,"alternative-id":["S0093775406000509"],"URL":"https:\/\/doi.org\/10.1053\/j.seminoncol.2006.01.021","relation":{},"ISSN":["0093-7754"],"issn-type":[{"value":"0093-7754","type":"print"}],"subject":[],"published":{"date-parts":[[2006,4]]}}}